Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MS patients get continued access to ocrelizumab in new study tracking physical impact

NCT ID NCT06675955

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers continued access to ocrelizumab for up to 500 people with multiple sclerosis who were already taking the drug in a previous Roche-sponsored trial. It aims to understand how MS affects daily physical activities like walking and using hands, from the patient's own point of view. Participants will receive either an IV infusion or a subcutaneous injection of ocrelizumab at approved doses. The study also monitors safety and side effects over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who were on ongoing ocrelizumab treatment on one of the following parent-studies \[Studies MN39159/CONSONANCE (NCT03523858), BN42082/MUSETTE (NCT04544436), BN42083/GAVOTTE (NCT04548999), BN44083/GLOBEAM, MN43978/CONSONANCE Ext., WA40404/O'HAND (NCT04035005), MN43964/OLERO (NCT05269004), GN41791/FENTREPID (NCT04544449), BP46016/MINTAKA, CN41144/OCARINA I-SC (NCT03972306), CN42097/OCARINA II-SC (NCT05232825)\] at the time of roll-over and who do not have access to the ocrelizumab treatment locally * The first dose of study treatment in this extension study will be received no earlier than 5 months after the last treatment in the parent study * Negative urine pregnancy test within 24 hours to first dose administered on MN45053 study treatment in participants of childbearing potential Exclusion Criteria: * Study treatment is commercially marketed in the participant's country for the participant-specific disease and is reasonably accessible to the participant * Study treatment is available via Post Trial Access Program (PTAP) in the participant's country and is accessible to the participant * Permanent premature discontinuation of study treatment for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable) * Any condition that, in the opinion of the investigator, would interfere with the interpretation of participant safety or place the participant at high risk for treatment-related complications * Concurrent participation in any therapeutic clinical trial (other than the parent study) * Immunocompromised state * Known active malignancy or are being actively monitored for recurrence of malignancy * Known presence of other neurological disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    43 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 5th Cherkasy City Center of Primary Health Care

    RECRUITING

    Cherkasy, 18029, Ukraine

  • Bukovinsky SMU RMI Chernivtsi RCH

    RECRUITING

    Chernivtsi, 58002, Ukraine

  • CH St Vincent de Paul

    RECRUITING

    Lille, 59000, France

  • CHU Amiens Hopital Sud

    RECRUITING

    Amiens Cedex1, 80054, France

  • CHU Brest Hopital La Cavale Blanche

    RECRUITING

    Brest, 29609, France

  • CHU De Caen

    RECRUITING

    Caen, 14033, France

  • CHU de Besancon Hopital Jean Minjoz

    RECRUITING

    Besançon, 25030, France

  • Center of Cardiology and Neurology

    RECRUITING

    Kirov, 610007, Russia

  • City Clinical Hospital #24

    RECRUITING

    Moscow, Moscow Oblast, 127015, Russia

  • City Hospital #40 of Kurortniy Administrative District

    RECRUITING

    Saint Petersburg, Sankt-Peterburg, 197706, Russia

  • Deutsche Klinik für Diagnostik

    RECRUITING

    Wiesbaden, 65191, Germany

  • FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency

    RECRUITING

    Krasnoyarsk, Krasnoyarsk Krai, 660037, Russia

  • FSBIH Siberian Regional Medical Centre of FMBA of Russia

    RECRUITING

    Novosibirsk, 630007, Russia

  • Federal center of brain research and neurotechnologies

    RECRUITING

    Moskva, Moscow Oblast, 117997, Russia

  • Groupe Hospitalier Pellegrin

    RECRUITING

    Bordeaux, 33076, France

  • GroupeHospitalo-Universitaire Caremeau

    RECRUITING

    Nîmes, 30029, France

  • Hopital Gabriel Montpied CHU de Clermont-Ferrand

    WITHDRAWN

    Clermont-Ferrand, 63003, France

  • Hopital Gui de Chauliac

    RECRUITING

    Montpellier, 34295, France

  • Hopital Nord Laennec

    RECRUITING

    Nantes, 44093, France

  • Hopital de Hautepierre

    RECRUITING

    Strasbourg, 67098, France

  • Hopital neurologique Pierre Wertheimer - CHU Lyon

    RECRUITING

    Bron, 69677, France

  • Hôpital Pasteur

    RECRUITING

    Nice, 06002, France

  • Krasnoyarsk State Medical Academy

    RECRUITING

    Krasnoyarsk, Krasnoyarsk Krai, 660022, Russia

  • LCC "Medical center "Unimed"

    RECRUITING

    Zaporizhzhia, 69035, Ukraine

  • LLC Osnova

    RECRUITING

    Saint Petersburg, Sankt-Peterburg, 197341, Russia

  • Lvivska oblasna tsentralna likarnia

    RECRUITING

    Lviv, 79010, Ukraine

  • Medical Center Dopomoga Plus

    RECRUITING

    Kyiv, 02123, Ukraine

  • Medical Center of Private Execution First Private Clinic

    RECRUITING

    Kyiv, 03037, Ukraine

  • Medical Clinical Research Center of Medical Center LLC Health Clinic

    RECRUITING

    Vinnytsi, 21009, Ukraine

  • Mun.Med.Proph.Inst.?Chernihiv Reg.Hosp.?

    RECRUITING

    Chernihiv, 14029, Ukraine

  • Municipal Non-profit Enterprise Zaporizhzhya Regional Hospital Zaporizhzhya Regional Council

    RECRUITING

    Zaporizhzhia, 69600, Ukraine

  • N.P. Bechtereva Institute of the Human Brain

    RECRUITING

    Saint Petersburg, Sankt-Peterburg, 197376, Russia

  • National Center of Social Significant Disease

    RECRUITING

    Saint Petersburg, Sankt-Peterburg, 197110, Russia

  • NeuroPoint Gesellschaft fur vorbeugende Gesundheitspflege mbH

    RECRUITING

    Ulm, 89073, Germany

  • Perm SMA n.a. academ. E.A. Vagner

    RECRUITING

    Perm, 614990, Russia

  • Regional Clinical Hospital

    RECRUITING

    Ivano-Frankivsk, 76008, Ukraine

  • Regional clinical hospital named after prof. S.V. Ochapovsky

    RECRUITING

    Krasnodar, 350086, Russia

  • SHI Sverdlovsk Regional Clinical Hospital #1

    RECRUITING

    Yekaterinburg, Sverdlovsk Oblast, 620102, Russia

  • SI USSRI of Medical and Social Problems of Disabilities of MOHU

    RECRUITING

    Dnipro, 49027, Ukraine

  • St.In.Inst. of Neurol.Psych.and Narcol.of the AMSU

    RECRUITING

    Kharkiv, 61068, Ukraine

  • Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz

    RECRUITING

    Westerstede, 26655, Germany

  • Ulyanovsk Regional Clinical Hospital

    RECRUITING

    Ulyanovsk, Ulyanovsk Oblast, 432063, Russia

  • Vertebronevrologiya LLC

    RECRUITING

    Kazan', Tatarstan Republic, 420043, Russia

  • Volyn Regional Clinical Hospital

    RECRUITING

    Lutsk, 43005, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.